Detailed dose evidence documented for Retatrutide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Not established
No approved labeled regimen
No established or recommended human dose.
Not applicable — no marketing authorization was identified in the major regulator databases reviewed as of the verification date.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
No established or recommended human dose.
Phase 2 and Phase 3 trials employed once-weekly subcutaneous administration with dose-escalation schedules. Phase 2 tested doses of 1, 4, 8, 12 mg; Phase 3 TRIUMPH/TRANSCEND programs use up to 12 mg weekly as the highest studied dose. Titration typically began at 2 mg.
Not established
What is not established
No safe or effective dose has been confirmed by regulatory review. Maximum tolerated dose, optimal titration rate, long-term safety (>2 years), and efficacy in diverse populations are not established.